Improvement of abdominal symptoms in people with Cystic Fibrosis during therapy with Elexacaftor/Tezacaftor/Ivacaftor brings gastrointestinal involvement into the paediatric pulmonologist's focus.
Journal: Klinische Padiatrie
Published:
Authors
Pauline Sadrieh, Lutz Nährlich, Carsten Schwarz, Olaf Eickmeier, Patience Eschenhagen, Louise Polte, Samira Dabelow, Franziska Duckstein, Carlos Zagoya, Jochen Mainz
Relevant Conditions